Main Logo
ASH20

Rebecca AraujoMyeloma | November 14, 2022
A study presented at the ASH Annual Meeting found that among 6 landmark multiple myeloma clinical trials, the ineligibility ...
Read More
Rebecca AraujoMyeloma | November 14, 2022
Iberdomide, an oral potent novel cereblon E3 ligase modulator (CELMoD), demonstrated an acceptable toxicity profile and ...
Rebecca AraujoMyeloma | January 5, 2021
DARA is an anti-CD38 antibody approved for the treatment of RRMM.
Rebecca AraujoTransplantation & Cellular Therapy | January 5, 2021
CT053 is a second-generation CAR T that incorporates a fully human BCMA-specific single-chain fragment variant.
Rebecca AraujoTransplantation & Cellular Therapy | November 14, 2022
Results from the PRIME study found that P-BCMA-101, an autologous CAR T-cell therapy, was effective and safe for patients ...
Ariel DeMaioMyeloma | November 14, 2022
Patients with high-risk myeloma may not be appropriately recognized as having high-risk disease at diagnosis, according to a ...
Rebecca AraujoMyeloma | November 14, 2022
Insurance status was found to be significantly associated with survival for patients with multiple myeloma, according to ...
Rebecca AraujoMyeloma | January 5, 2021
Individuals with MM are at increased risk for developing VTE.